Real-World Evidence From More Than 1000 Patients Treated With Adalimumab For Moderate-to-Severe Psoriasis in the Czech Republic.

Martina KojanovaPetra CetkovskaDaniela StrosovaJorga FialovaPetr ArenbergerTomas DolezalSpyridon Gkalpakiotisnull null

Published in: Dermatology and therapy (2021)

Baseline factors including PASI, number of previous biological therapies, and sex were associated with shorter adalimumab survival. This long-term study shows that adalimumab is effective and has high treatment persistence.

Keyphrases

rheumatoid arthritis
juvenile idiopathic arthritis
hidradenitis suppurativa
ulcerative colitis
systemic lupus erythematosus